Large-Scale Synthesis and Patents for Abrocitinib
The synthesis of abrocitinib, a JAK1 inhibitor used to treat atopic dermatitis, has been described in various patent applications. These patents often detail specific chemical routes and purification methods suitable for large-scale production [1].
How is Abrocitinib Made on a Large Scale?
Large-scale synthesis of abrocitinib typically involves multi-step chemical reactions. Patents disclose methods that aim to optimize yield, purity, and efficiency for manufacturing. For example, one route described involves reacting key intermediates under specific conditions to form the final drug substance [1]. Purification steps, such as crystallization, are also crucial for obtaining the high purity required for pharmaceutical use [1].
What Patents Protect Abrocitinib Synthesis?
Several patents cover the synthesis and manufacturing processes of abrocitinib. These intellectual property filings are essential for protecting the commercial interests of the drug's developer, Pfizer [2]. DrugPatentWatch.com tracks such patents, providing information on their status and expiration dates [1]. Identifying these synthesis patents can be important for generic manufacturers seeking to develop alternative production methods or prepare for market entry after patent expiry [1].
When Do Abrocitinib Patents Expire?
The patent landscape for abrocitinib, including those covering its synthesis, is complex and dynamic. The expiration of key patents, particularly those related to the compound itself and its methods of use, will eventually allow for the introduction of generic versions [1]. DrugPatentWatch.com is a resource that can provide detailed information on specific patent expiry dates for abrocitinib [1].
Who Developed Abrocitinib?
Abrocitinib was developed by Pfizer Inc. [2].
What Are Other Treatments for Atopic Dermatitis?
Besides abrocitinib, other treatments for atopic dermatitis include topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and other systemic immunomodulators such as dupilumab and upadacitinib [3].
Sources:
[1] DrugPatentWatch.com
[2] Pfizer Inc.
[3] National Eczema Association